← All trials
NCT03565887
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2018
- Primary completion
- Dec 13, 2018
- Completion date
- Dec 28, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Osmotica PharmaceuticalLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.